Clinical trials: Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus
Glycemic Holter Study (Continuous Glucose Monitoring) -
The study will assess glycemic variability and optimized glycemic control in T2DM patients treated with a DPP-4 inhibitor as add-on therapy to metformin.
- Trial name
- OPTIMA (NCT01193296)
- Testing
- Vildagliptin, Sitagliptin
- Where
- 7 sites in France
- Volunteers
- 36 people
- Sponsor
- Novartis
Fatty Liver
The Effect of a Probiotic on Hepatic Steatosis
Non-alcoholic fatty liver disease (NAFLD) is an accumulation of fat and fibrous tissue in the liver. It is the most common cause of chronic liver disease in the United States.
- Trial name
- NCT00099723
- Testing
- VSL#3
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- VSL Pharmaceuticals
Type 2 Diabetes Mellitus
A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)
Ertugliflozin (PF-04971729, MK-8835) is a new compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this study is to evaluate the safety and tolerability along with the pharmacokinetics of single…
- Trial name
- NCT00989079
- Testing
- Ertugliflozin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes
The purpose of this study is to compare LY900014 to insulin lispro, both in combination with insulin glargine or insulin degludec, in participants with type 2 diabetes (T2D).
- Trial name
- PRONTO-T2D (NCT03214380)
- Testing
- LY900014, Insulin Lispro, Insulin Glargine
- Where
- 141 sites in United States, Argentina and 14 more
- Volunteers
- 933 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Diabetes Study to Treat A Population Previously Not at Target
This study will assess if customizing the start dose of rosuvastatin appropriate for the degree of LDL-C reduction required, would achieve LDL-C target of ≤ 2.0 mmol/L quickly with either no titration or just one titration step…
- Trial name
- ADAPT (NCT00747149)
- Testing
- Rosuvastatin
- Where
- 84 sites in Canada
- Volunteers
- 598 people
- Sponsor
- AstraZeneca
Hypercholesterolemia, Mixed Dyslipidemia
Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
The purpose of this study is to evaluate the effect of 12 weeks of subcutaneous evolocumab taken monthly compared with subcutaneous placebo taken monthly on low density lipoprotein cholesterol (LDL-C) in adults with type 2…
- Conditions
- Hypercholesterolemia, Mixed Dyslipidemia, Type 2 Diabetes
- Trial name
- BANTING (NCT02739984)
- Testing
- Evolocumab
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 424 people
- Sponsor
- Amgen
Type 2 Diabetes Mellitus
Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the safety and efficacy of MP-513 in combination with Metformin in patients with type 2 diabetes for 24 weeks administration and to evaluate the safety and efficacy of MP-513 in…
- Trial name
- NCT00971243
- Testing
- MP-513 Lowest Dose and Metformin, MP-513 Low Dose and Metformin, MP-513 Medium Dose and Metformin
- Where
- 44 sites in Denmark, Germany and 5 more
- Volunteers
- 448 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes Mellitus, Metabolic Syndrome
Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome
This is a Phase 2, multi-center, double-blind, placebo-controlled study of the safety and effect of PBI-4050 at doses ranging from 400 mg to 1200 mg on relevant biomarkers in subjects with inadequately-controlled T2DMS on stable…
- Trial name
- NCT03081598
- Testing
- PBI-4050
- Where
- 11 sites in Canada
- Volunteers
- 104 people
- Sponsor
- Liminal BioSciences Ltd.
Diabetes Mellitus, Type 2 Diabetes
Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)
The purpose of the study is to assess the safety of the addition of sitagliptin, and its effect on hemoglobin A1c (A1C) in pediatric participants 10-17 years of age with type 2 diabetes mellitus (T2DM) with inadequate glycemic…
- Trial name
- NCT01485614
- Testing
- Sitagliptin, Metformin, Glycemic Rescue 1
- Volunteers
- 200 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
A Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination with Metformin in Chinese Subjects in China with Type 2 Diabetes…
- Trial name
- NCT02104804
- Testing
- Saxagliptin 5mg
- Where
- 11 sites in China
- Volunteers
- 953 people
- Sponsor
- AstraZeneca
Type2 Diabetes
DCB-DM101 in Healthy Volunteers and for Type 2 Diabetes Mellitus Patients
An Open-Label Phase I Study to Assess the Safety and Tolerability Profile of Three Escalating Doses of DCB-DM101 in Healthy Volunteers and Optimum Dose of DCB-DM101 as Add-on Treatment in Type 2 Diabetes Mellitus (T2DM) Patients
- Trial name
- NCT03033433
- Testing
- DCB-DM101
- Where
- Taiwan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- VitNovo, Inc.
Diabetes Mellitus, Type 2
To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus
This observation study is designed as a prospective, multi-organ observation study to confirm the blood sugar control effect and safety of ENVLO tablet or Envlomet SR Tablet administration for 24 weeks in patients with type 2…
- Trial name
- NCT05926414
- Testing
- Enavogliflozin
- Where
- South Korea
- Volunteers
- 15,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus Type 2
Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to assess the effect of EGT0001442 on fasting plasma glucose after 28 days of treatment in subjects with type 2 diabetes.
- Trial name
- NCT01029704
- Testing
- EGT0001442
- Where
- 12 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Theracos
Diabetes Mellitus, Type 2, Kidney Function Tests
The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.
The purpose of this study is to evaluate how dapagliflozin mechanism of action is impacted by Type 2 Diabetes Mellitus status and kidney function
- Trial name
- DAPASALT (NCT03152084)
- Testing
- Dapagliflozin
- Where
- 4 sites in Netherlands, Sweden
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus
This trial will compare the use of fixed dose combination of empagliflozin and linagliptin to linagliptin alone in patient with type 2 diabetes mellitus
- Trial name
- NCT02453555
- Testing
- Linagliptin, Empagliflozin + linagliptin low dose, Empagliflozin + linagliptin high dose
- Where
- 40 sites in Japan
- Volunteers
- 275 people
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)
Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components
A Study to Assess the Bioequivalence of the fixed dose combination (FDC) of Dapagliflozin and Sitagliptin, and Dapagliflozin 10 mg and Sitagliptin 100 mg administered as individual tablets in Healthy Subject
- Trial name
- NCT05266404
- Testing
- Dapagliflozin/sitagliptin FDC, Sitagliptin, Dapagliflozin
- Where
- Germany
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Treatment Use of Generex Oral-lyn™ in Patients With Diabetes
The objective of this Treatment IND protocol is to provide Generex Oral-lyn™ to patients with serious or life-threatening Type 1 or Type 2 diabetes mellitus, with no satisfactory alternative therapy available for treatment of…
- Trial name
- NCT00948493
- Testing
- Buccal insulin spray
- Sponsor
- Generex Biotechnology Corp.
Diabetes Mellitus, Type 2
An Assessment of Pharmacokinetic Gemigliptin and Metformin Interactions in Healthy Mexican Volunteers
This is an open, randomized (randomization ratio: 1:1), multiple dose, three way, three period cross over study to assess the potential for drug drug interactions between gemigliptin (a DPP-IV inhibitor mainly metabolized by…
- Trial name
- NCT03310749
- Testing
- Gemigliptin, Gemigliptin 50 mg q.d. + metformin 1000 mg twice a day, Metformin
- Where
- Mexico
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Stendhal Americas, S.A.
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes
GSK189075 is intended for use as a single treatment or in combination with other treatments for tye 2 diabetes mellitus (T2DM). Metformin is widely used in Europe and the USA for the treatment of T2DM.
- Trial name
- NCT00376038
- Testing
- GSK189075 oral tablets, metformin tablets
- Where
- Mexico
- Volunteers
- 13 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
This is a Phase 1, randomized, double-blind, placebo-controlled, first-in-human (FIH) study to evaluate the safety, tolerability, food effect (FE), pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered XW014 in…
- Trial name
- NCT05579314
- Testing
- XW014
- Where
- 3 sites in United States
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Sciwind Biosciences USA Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.